Transcatheter aortic valve replacement (TAVR) is becoming the new standard of care for the treatment of aortic valve pathologies, irrespective of the surgical risk. A new generation of both self-expanding (SE) and balloon-expandable valves with Conformité Européene (CE) or Food and Drug Administration (FDA) mark approval for clinical use is spreading. Additionally, emerging countries such as China and India have developed new devices, which are currently available on the market in some countries. The current generation of transcatheter heart valves (THVs) aims to overcome or reduce the major limitations of first-generation valves such as paravalvular leak, vascular complications, cardiac rhythm disturbances, and stroke. Below, we describe the technical features and first clinical results of commercially available TAVR devices.